強
強気
強気 · 25%CLGN
$10.06
シナリオ価格
$3.970
+0.030 (+0.76%)終値時点
Loading chart…
- 高値
- 4.189
- 始値
- 4.180
- 出来高加重平均価格
- 4.00
- 出来高
- 29.22K
- 時価総額
- 57.27M
- 安値
- 3.850
- 売買代金
- 116.96K
- EV/EBITDA（TTM）
- -0.06
CollPlant Biotechnologies Ltd, formerly known as Collplant Holdings Ltd, is a company dealing in aesthetic medicine and regenerative medicine based in Israel. The company provides products and technologies for broadly understood regenerative medicine, including tissue regeneration and organ production. The technology is based on plants and is based on the production of collagen type I (rhCollagen).
AI分析 of Collplant Biotechnologies Ltd (CLGN)
中立CollPlant Biotechnologies Ltd is not a strong buy right now due to its current price of $3.97, which is significantly below its 52-week high of $22.50, indicating a potential for recovery but also high risk. The company has a forward P/E ratio of 80, suggesting that it is highly valued relative to its earnings, which are currently negative. Additionally, the RSI is at 47.809, indicating a neutral momentum, and the stock has experienced a year-to-date change of -73.18%, reflecting ongoing challenges. The main risk is its high volatility, with an implied volatility of 671.43%, which could lead to significant price swings.
バリュエーション指標
Collplant Biotechnologies Ltd（CLGN）の現在の予想PERは80.00で、5年平均は16.78です。
Alphio AI による CLGN の価格シナリオ
シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト（25 / 50 / 25）であり、保証ではありません。
イベントタイムライン
ニュース
8.510-09PRnewswireCollPlant Secures Private Placement to Accelerate R&D
3.510-06PRnewswireCollPlant Advances Photonic Computing Strategy
3.510-06NewsfilterCollPlant Advances Photonic Computing Strategy Through LightSolver's IP Growth
8.509-30PRnewswireCollPlant Expands into Photonic Computing with LightSolver Acquisition
- 8.509-30Newsfilter
CollPlant Acquires LightSolver to Expand Technology Portfolio
CLGN のよくある質問 — Alphio AI が回答
CollPlant Biotechnologies Ltd, formerly known as Collplant Holdings Ltd, is a company dealing in aesthetic medicine and regenerative medicine based in Israel. The company provides products and technologies for broadly understood regenerative medicine, including tissue regeneration and organ production. The technology is based on plants and is based on the production of collagen type I (rhCollagen). It operates in the Healthcare sector (ORTHOPEDIC, PROSTHETIC, AND SURGICAL APPLIANCES AN industry).
CollPlant Biotechnologies Ltd is not a strong buy right now due to its current price of $3.97, which is significantly below its 52-week high of $22.50, indicating a potential for recovery but also high risk. The company has a forward P/E ratio of 80, suggesting that it is highly valued relative to its earnings, which are currently negative. Additionally, the RSI is at 47.809, indicating a neutral momentum, and the stock has experienced a year-to-date change of -73.18%, reflecting ongoing challenges. The main risk is its high volatility, with an implied volatility of 671.43%, which could lead to significant price swings.
コミュニティ
もっと見る ↗投稿はまだありません
登録またはログインして議論に参加関連記事
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。